angiotensinogen and Anemia--Sickle-Cell

angiotensinogen has been researched along with Anemia--Sickle-Cell* in 4 studies

Other Studies

4 other study(ies) available for angiotensinogen and Anemia--Sickle-Cell

ArticleYear
Urinary angiotensinogen is associated with albuminuria in adults with sickle cell anaemia.
    British journal of haematology, 2023, Volume: 202, Issue:3

    We explored the association of novel urinary biomarkers with albumin-creatinine ratio (ACR) in adults with sickle cell anaemia. Of 37 participants, 13 (35.2%) had persistent albuminuria (PA). Urinary levels of clusterin (p = 0.002), retinol-binding protein 4 (p = 0.008), alpha-1 microglobulin (p = 0.002) and angiotensinogen (p = 0.006) were significantly higher in participants with PA than in those without PA. Although univariate analysis showed significant associations between both alpha-1 microglobulin (p = 0.035) and angiotensinogen (p = 0.0021) with ACR, only angiotensinogen was associated with ACR in multivariable analysis (p = 0.04). Our results suggest that urinary angiotensinogen may identify sickle cell anaemia patients at risk for kidney disease.

    Topics: Adult; Albuminuria; Anemia, Sickle Cell; Angiotensinogen; Biomarkers; Creatinine; Humans; Kidney Diseases

2023
Angiotensinogen M235T Gene Polymorphism is a Genetic Determinant of Cerebrovascular and Cardiopulmonary Morbidity in Adolescents with Sickle Cell Disease.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2019, Volume: 28, Issue:2

    Cerebrovascular stroke is a common critical complication of sickle cell disease (SCD). Angiotensinogen (AGT) M235T gene polymorphism is associated with risk of ischemic stroke and cardiovascular disease.. We investigated the potential association between angiotensinogen M235T gene polymorphism and susceptibility to cerebrovascular and cardiopulmonary complications in adolescents with SCD.. Forty-six patients with SCD in steady state were studied stressing on history of stroke, hydroxyurea/chelation therapy, hematological profile, and echocardiographic findings. Polymerase chain reaction-based restriction fragment length polymorphism analysis was used to detect AGT M235T gene polymorphism. Fifty sex- and age-matched healthy controls were enrolled for assessment of M235T gene polymorphism pattern.. The distribution of AGT M235T gene polymorphism was similar between SCD patients and healthy controls. The frequency of T allele of AGT M235T gene polymorphism (TT and MT genotypes) was significantly higher among patients with history of manifest stroke (P < .001). Patients with TT and MT genotypes had higher incidence of cardiopulmonary complications (P = .041) as well as higher percentage of HbS (P < .001) and lower hemoglobin level (P = .008) compared with those with MM genotype. Serum ferritin, liver iron concentration, and cardiac T2* were not related to T alleles or genotypes. Logistic regression analysis revealed that M235T genotype was a significant independent factor related to the occurrence of stroke among patients with SCD (Odds Ratio 14.05, 95% confidence interval 3.82-28.91; P = .001).. AGT M235T gene polymorphism may represent a genetic modifier to vascular morbidities in Egyptian patients with SCD.

    Topics: Adolescent; Age Factors; Anemia, Sickle Cell; Angiotensinogen; Case-Control Studies; Cerebrovascular Disorders; Egypt; Female; Gene Frequency; Genes, Modifier; Genetic Association Studies; Genetic Predisposition to Disease; Heart Diseases; Humans; Lung Diseases; Male; Phenotype; Polymorphism, Genetic; Risk Factors; Young Adult

2019
Angiotensinogen gene associated polymorphisms and risk of stroke in sickle cell anemia: Additional data supporting an association.
    American journal of hematology, 2004, Volume: 76, Issue:3

    Topics: Adolescent; Anemia, Sickle Cell; Angiotensinogen; Child; Child, Preschool; Genetic Predisposition to Disease; Humans; Polymorphism, Genetic; Stroke

2004
Polymorphisms within the angiotensinogen gene (GT-repeat) and the risk of stroke in pediatric patients with sickle cell disease: a case-control study.
    American journal of hematology, 2001, Volume: 68, Issue:3

    Stroke is one of the most devastating complications of patients with sickle cell disease (SCD). Currently, there are no known molecular or genetic markers that can be used to assess the risk of stroke in this population. We have previously shown that relative hypertension may be one risk factor for stroke in SCD. In a case-control study, we investigated the association between GT-repeat polymorphism within the angiotensinogen (AGT) gene and the risk of stroke in pediatric patients with SCD. After informed consent was obtained, 63 patients (21 stroke subjects and 42 nonstroke control subjects matched according to age and sex) with SCD followed at local pediatric hematology clinics were genotyped to test the association of specific GT-repeat alleles of the AGT gene and occurrence of stroke. There were statistical differences in the distribution of the genotypes among stroke and nonstroke SCD patients (chi(2) = 10.82, df = 11, P < 0.05). We also found GT-repeat alleles A3 and/or A4 of the AGT gene conferred a four-fold increase in the risk of stroke (odds ratio [OR] = 4, P < 0.05). The attributable odds ratio for allele A3 and A4 is 2.24 and 4.33, respectively (P < 0.005). Our results suggest that GT-repeat within the AGT gene may be associated with risk of stroke in pediatric SCD. The relative risk of stroke in the presence of alleles A3 and/or A4 is fourfold greater than in the absence of these alleles. If these data are substantiated in a larger cohort of patients, our results indicate that the determination of GT-repeat of AGT gene may be a useful genetic marker to assess the risk for stroke of patients with SCD. Am. J. Hematol. 68:164-169, 2001. Published 2001 Wiley-Liss, Inc.

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Angiotensinogen; Case-Control Studies; Child; Child, Preschool; Dinucleotide Repeats; Female; Gene Frequency; Genetic Markers; Humans; Male; Odds Ratio; Polymorphism, Genetic; Risk Factors; Serine Proteinase Inhibitors; Stroke

2001